If you cannot press your palm flat against a table, the most likely explanation is Dupuytren’s contracture, a condition in which thick cords of tissue form beneath the skin of the palm and gradually pull one or more fingers into a permanently bent position. The condition has been recognized since the early 1830s, when the French surgeon Guillaume Dupuytren published detailed descriptions of it, and it remains one of the most common hand disorders in people of Northern European descent.1PubMed Central. An insight into Dupuytren’s contracture. What makes it tricky is how slowly it develops: by the time you notice your hand won’t flatten, years of tissue change have already taken place beneath the surface.
The Tabletop Test and Early Warning Signs
The simplest self-check is called the tabletop test. You place your hand flat on a hard surface, palm down. If your hand lies completely flat, Dupuytren’s is unlikely to be causing problems at that moment. If one or more fingers remain raised and you cannot push them down without pain or resistance, that is a strong indicator. The ring finger and little finger are the ones most commonly affected, though any finger can be involved.
Before you reach the point where the tabletop test is positive, there are usually earlier clues. The first is often a small, firm lump or nodule in the palm, usually near the base of the ring or little finger. This nodule may be tender at first but often becomes painless over time. As the disease progresses, a cord-like band develops under the skin, running from the palm into the affected finger. That cord slowly tightens, and the finger begins to curl inward. Grasping large objects, shaking hands, putting on gloves, or reaching into a pocket becomes harder. Many people adapt without noticing how much function they have lost until the contracture is fairly advanced.
What Is Happening Under the Skin
Dupuytren’s is fundamentally a disease of uncontrolled connective-tissue growth in the palmar fascia, the sheet of tough tissue that lies just beneath the skin of your palm. The process moves through roughly three stages. In the first, proliferative stage, the tissue fills with rapidly dividing cells, particularly a type called myofibroblasts, which are cells that can both produce collagen and contract like muscle. In the second stage, those cells begin laying down large amounts of collagen and actively contracting, pulling the finger inward. In the final, residual stage, the cells slow down and the tissue becomes a dense, relatively inactive cord of scar-like material.2PubMed Central. The Rationale for Treating the Nodule in Dupuytren’s Disease
Research on the molecular signals driving the process has identified several key players. The inflammatory molecule TNF (tumor necrosis factor) appears to act through a signaling cascade called the Wnt pathway to push cells toward fibrosis and contraction.3PubMed Central. Unraveling the signaling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a therapeutic target Meanwhile, another growth signal, TGF-β1, appears to cross-talk with the same Wnt pathway, silencing the body’s natural brakes on fibrotic tissue production.4PubMed. Wnt pathway in Dupuytren disease: connecting profibrotic signals The nodules themselves are busy places: they contain high numbers of proliferating cells, macrophages (immune cells involved in tissue remodeling), and elevated levels of several collagen types and a structural protein called fibronectin compared to the mature cords.5PubMed Central. Matrix and cell phenotype differences in Dupuytren’s disease Understanding these signals matters because they are now being used to identify potential drug targets.
Who Gets Dupuytren’s and Why
Dupuytren’s has a strong genetic component. If you have a first-degree relative with the condition, your risk is substantially higher. A study of genetic risk scoring found that people who developed the disease before age 50 and who had a family history of it carried the highest genetic risk burden.6PubMed. Dupuytren diathesis and genetic risk Men are affected more often than women, and the condition becomes more common with age, with most diagnoses occurring after age 50.
Beyond genetics, two metabolic factors stand out. Diabetes roughly doubles the risk. In a large study following over 30,000 people for more than 20 years, diabetes was independently associated with developing Dupuytren’s in both men and women, even after accounting for age, weight, alcohol use, smoking, and manual work.7Scientific Reports. Metabolic factors and the risk of Dupuytren’s disease: data from 30,000 individuals followed for over 20 years Alcohol consumption is the other significant metabolic risk factor. That same study found a clear, dose-dependent link between moderate-to-heavy drinking and Dupuytren’s in both sexes, and a separate Mendelian randomization study confirmed a causal relationship between drinks per week and the disease, with roughly a threefold increase in odds among heavier drinkers.8PubMed Central. Smoking, alcohol consumption and risk of Dupuytren’s disease: a Mendelian randomization study
Smoking, by contrast, does not appear to be an independent risk factor. Neither the large cohort study nor the Mendelian randomization analysis found a significant link between smoking and Dupuytren’s.7Scientific Reports. Metabolic factors and the risk of Dupuytren’s disease: data from 30,000 individuals followed for over 20 years This surprises many people, because smoking is often listed as a risk factor in older patient handouts. The evidence has moved on.
Does Manual Work Cause It?
The relationship between hand work and Dupuytren’s is real, but it takes decades to show up. A case-control study found that the risk becomes substantial after roughly 30 years of sustained repetitive handwork, with no clear independent effect from shorter exposures or from hand-held vibrating tools alone.9PubMed. Dupuytren’s contracture and handwork: A case-control study Vibration exposure, however, tells a sharper story when analyzed separately. A meta-analysis of nine studies found that people exposed to hand-transmitted vibration had nearly triple the odds of developing Dupuytren’s compared to unexposed controls.10PubMed. Dupuytren’s Disease and exposure to vibration: Systematic review and Meta-analysis Another study found that men with high levels of weekly vibration exposure had more than twice the risk, even after adjusting for other factors.11Occupational and Environmental Medicine. Dupuytren’s contracture and occupational exposure to hand-transmitted vibration So if you work with jackhammers, power drills, or heavy vibrating machinery for years, the risk is meaningful. For most office or light-manual workers, occupation is not the main driver.
The Viking Myth
You may have heard Dupuytren’s called “the Viking disease,” the idea being that Norse raiders spread the gene for it across Northern Europe. It is a colorful story, but a genetic study that cross-referenced genome-wide data from Dupuytren’s patients with detailed ancestry data from the People of the British Isles project found no evidence at all for an excess of Norse ancestry in people with the disease.12PubMed. Is Dupuytren’s disease really a ‘disease of the Vikings’? The condition is genuinely more common among people of Northern European descent, but pinning it on the Vikings specifically is a myth unsupported by modern genetics.
Conditions That Travel With Dupuytren’s
Some people with Dupuytren’s develop related fibrotic growths elsewhere in the body. The same type of abnormal tissue can show up on the soles of the feet (Ledderhose disease), on the knuckles (Garrod’s pads), or in the connective tissue of the penis (Peyronie’s disease). These conditions share a common inheritance pattern, similar risk factors, and overlapping biology.13PubMed. Dupuytren contracture as a sign of systemic disease When multiple fibrotic sites are involved, clinicians refer to this as “Dupuytren diathesis,” which broadly means the person has a stronger genetic predisposition and is more likely to experience aggressive disease and recurrence after treatment.14PubMed Central. Dupuytren’s disease
Dupuytren diathesis is worth knowing about because it changes the treatment conversation. If you developed the disease young, have a family history, and also have lumps on your feet or knuckle pads, you and your surgeon may want to plan for a higher likelihood of recurrence regardless of which procedure you choose.
Things That Look Like Dupuytren’s but Aren’t
A nodule in the palm does not always mean Dupuytren’s. Trigger finger, for example, causes a lump at the base of a finger that can be confused with a Dupuytren’s nodule, but the mechanism is different: it involves a swollen tendon catching in its sheath, producing a snapping or locking sensation. Flexor sheath ganglion cysts can also present as a firm lump in a similar location. A simple clinical exam technique can help differentiate these: the hallmark of Dupuytren’s is that the lump is fixed to the skin and does not move when you bend and straighten the finger, whereas trigger-finger nodules and ganglion cysts shift with tendon movement.15PubMed Central. A Simple Physical Exam Maneuver to Distinguish Trigger Digit, Dupuytren’s Nodule, and Flexor Sheath Ganglion If you are unsure what your hand lump is, a hand specialist can usually tell the difference during a brief office visit. Imaging is available but is mainly useful for tracking disease activity over time rather than making the initial diagnosis.16PubMed Central. Imaging for Dupuytren disease: a systematic review of the literature
Treatment Options, From Least to Most Invasive
Treatment for Dupuytren’s generally is not recommended until the contracture begins to interfere with daily activities. The traditional threshold is a positive tabletop test or a contracture of about 30 degrees or more at the affected joint. Once you cross that line, there are three main approaches.
Needle Aponeurotomy
This is the least invasive option. A doctor inserts a needle through the skin and uses it to perforate and weaken the cord, then manually straightens the finger. It can be done in an office setting under local anesthesia. Recovery is fast: patients in one study were discharged from follow-up after an average of about five weeks, compared to over 23 weeks for open surgery.17SVOA Orthopaedics. Comparative Surgical Management of Dupuytren´s Contracture: Percutaneous Needle Aponeurotomy vs Limited Open Fasciectomy Complication rates are lower and patient-reported satisfaction, daily-activity scores, and pain scores tend to favor needle aponeurotomy over open surgery in the short term.18PubMed. Comparative Effectiveness of Percutaneous Needle Aponeurotomy and Limited Fasciectomy for Dupuytren’s Contracture: A Multicenter Observational Study The trade-off is a higher recurrence rate.
Collagenase Injection
Collagenase clostridium histolyticum is an enzyme injected directly into the cord. It dissolves the collagen that makes up the cord, and the next day the doctor manipulates the finger straight. In a pivotal trial, joints injected with collagenase achieved the primary improvement endpoint about 64% of the time, compared to roughly 7% with placebo, and the average range of motion nearly doubled.19PubMed. Injectable Collagenase Clostridium Histolyticum for Dupuytren’s Contracture A systematic review concluded that collagenase provides better outcomes for mild-to-moderate contractures than open surgery, with a shorter recovery period and a low rate of serious side effects.20PubMed Central. Collagenase clostridium histolyticum in Dupuytren’s contracture: a systematic review Serious complications are rare but have included tendon rupture and, in isolated cases, skin loss severe enough to require amputation.21PubMed Central. Complications Following Collagenase Treatment for Dupuytren Contracture It is worth noting that availability varies by country; collagenase was withdrawn from the European market in 2020 for commercial reasons and remains unavailable in some regions.
Surgery
Limited fasciectomy, where the surgeon cuts out the diseased tissue through an incision in the palm, is the traditional approach and still the most durable. Dermofasciectomy goes further: it removes the overlying skin as well and replaces it with a skin graft. In a study comparing the two, the overall recurrence rate after surgery was about 47%, but dermofasciectomy prevented virtually all recurrence of Dupuytren’s tissue in the grafted area.22PubMed. Dupuytren’s contracture: a comparative study of fasciectomy and dermofasciectomy in one hundred patients Surgery involves a longer recovery, with hand therapy often required for weeks, and carries higher complication rates including nerve injury.
Recurrence Is the Rule, Not the Exception
Whatever treatment you choose, Dupuytren’s tends to come back. A systematic review of prospective data with two-to-seven-year follow-up found that joints treated with limited fasciectomy had the lowest recurrence rate at about 17%, followed by collagenase at about 33% and needle aponeurotomy at roughly 46%.23Journal of Hand Surgery Global Online. Likelihood of Dupuytren Contracture Recurrence After Limited Fasciectomy, Needle Aponeurotomy or Collagenase Clostridium histolyticum: Systematic Review of Prospective Data With 2- to 7-Year Follow-up One useful pattern: contractures at the knuckle joint closest to the palm (MCP joint) were about two-thirds less likely to recur than those at the middle finger joint (PIP joint), regardless of treatment type.
This recurrence reality shapes treatment strategy. Because most people will need more than one intervention over a lifetime, cost-effectiveness analyses have looked at sequencing. One modeling study found that starting with needle aponeurotomy for initial and recurrent episodes was the most cost-effective strategy for nearly every joint type and severity level.24PubMed Central. Cost-effectiveness of Recurrent Dupuytren Contracture Treatment Saving the more invasive, expensive surgery for a second or third recurrence makes economic sense when the disease is likely to return regardless. A Japanese study comparing collagenase to surgery directly also found that the surgery group incurred higher direct costs while producing similar functional results after adjustment.25Scientific Reports. The CeCORD-J study on collagenase injection versus aponeurectomy for Dupuytren’s contracture compared by hand function and cost effectiveness
Does Post-Surgery Splinting Help?
After fasciectomy or dermofasciectomy, many hand therapists prescribe a night splint to hold the finger straight while you heal. This practice is deeply ingrained, but the evidence behind it is surprisingly thin. A randomized controlled trial comparing night splinting for six months after surgery to no splinting found no significant differences in hand function scores, total extension deficit, or patient satisfaction at one year.26PubMed Central. Night-time splinting after fasciectomy or dermo-fasciectomy for Dupuytren’s contracture: a pragmatic, multi-centre, randomised controlled trial A separate systematic review of the available data on post-operative splinting reached a similar conclusion: the evidence is low-quality and equivocal, and while some patients wearing a splint showed improved extension, they also lost some finger flexion and overall hand function.27PubMed Central. Clinical effectiveness of post-operative splinting after surgical release of Dupuytren’s contracture: a systematic review If your surgeon recommends a splint, it is not unreasonable to follow their advice, but you should know the benefit is unproven.
Living With Dupuytren’s
The physical limitations are obvious, but the emotional and social effects of Dupuytren’s often go unmentioned. Studies exploring patient experience have found that the disease affects daily activities across a broad range: dressing, gripping, personal hygiene, cooking, and recreational activities all become harder as contractures worsen.28PubMed. The impact of Dupuytren disease on patient activity and quality of life Beyond practical limitations, men living with the condition have described feelings of embarrassment, fear of injuring the hand, and a sense of aging or decline. Many quietly adapt by avoiding activities or performing them with less precision, rather than seeking help.29PubMed. Experiences of men living with Dupuytren’s disease-Consequences of the disease for hand function and daily activities A scoping review of patient perspectives found that mental health, mobility, social participation, and self-care were the domains most frequently impacted.30Journal of Hand Therapy. Patients’ perspectives on Dupuytren’s disease: A scoping review and categorization using the WHO International Classification of Functioning, Disability and Health Framework (ICF)
One of the frustrations patients report is the “watch and wait” advice they receive in early stages. When you can feel a lump forming and your finger is starting to stiffen, being told there is nothing to do until the contracture is severe enough for surgery can feel dismissive. This frustration has driven interest in treatments aimed at the early, nodular stage of the disease.
A Drug That Might Treat It Early
The identification of TNF as a driver of Dupuytren’s fibrosis led to clinical trials of adalimumab, a TNF-blocking drug already widely used for rheumatoid arthritis and other inflammatory conditions. In a phase 2b randomized, double-blind, placebo-controlled trial, four injections directly into the nodule at three-month intervals produced decreases in both nodule hardness and size on ultrasound at 12 months. Those improvements continued even at 18 months, nine months after the final injection.31PubMed Central. Treatments for early-stage Dupuytren’s disease: an evidence-based approach This is still early-phase research, and other early-stage treatments such as steroid injections and radiotherapy lack strong trial evidence. But adalimumab represents a genuinely different approach: intervening at the biological level before a cord forms, rather than waiting to cut or dissolve one that already has.